BioTuesdays

Category - Markets

Alpha Tau
Markets

Cantor starts Alpha Tau Medical at OW; PT $20

Cantor Fitzgerald launched coverage of Alpha Tau Medical (NASADQ:DRTS) with an “overweight” rating and $20 price target. The stock closed at $10.58 on April 13. Alpha Tau, which went public in March 2022, is a medical...

April 14, 2022
Synaptogenix
Markets

Maxim starts Synaptogenix at buy; PT $14

Maxim Group launched coverage of Synaptogenix (NASDAQ:SNPX) with a “buy” rating and price target of $14. The stock closed at $7.03 on April 11. Synaptogenix, formerly Neurotrope, is continuing development of bryostatin...

April 12, 2022
Syndax Pharma Logo
Markets

HCW starts Syndax Pharma at buy; PT $31

H.C. Wainwright initiated coverage of Syndax Pharmaceuticals (NASDAQ:SNDX) with a “buy” rating and $31 price target. The stock closed at $17.51 on April 8. Syndax is a clinical-stage biopharmaceutical company focused on...

April 11, 2022
Dyadic
Markets

Dawson James halves Dyadic PT to $3

Dawson James halved its price target for Dyadic International (NASDAQ:DYAI) to $3 from $6, citing the company’s C1 platform and whether it will be adopted by a major vaccine maker anytime soon. The stock closed at $2.48...

April 8, 2022
Agile Therapeutics
Markets

Maxim cuts Agile Therapeutics to hold; removes PT

Maxim Group downgraded Agile Therapeutics (NASDAQ:AGRX) to “hold” from “buy” and removed its price target, citing a financing overhang. The stock closed at 16 cents on April 7. Analyst Naz Rahman writes that Agile ended...

April 8, 2022
Gracell Biotechnologies
Markets

BTIG starts Gracell at buy; PT $18 

BTIG initiated coverage of Gracell Biotechnologies (NASDAQ:GRCL) with a “buy” rating and $18 price target, “with upside potential driven by value inflection points in the next 12-to-24 months.” The stock closed at $2.33...

April 4, 2022
ayala logo
Markets

Maxim lowers Ayala Pharma PT to $12 from $22

Maxim Group reduced its price target for Ayala Pharmaceuticals (NASDAQ:AYLA) to $12 from $22, but maintained a “buy” rating, after the company discontinued the Phase 2 TENANCITY trial evaluating AL101 in triple negative...

March 30, 2022